Ambient AI has made it easier for clinicians to turn patient conversations into documentation. FDB and Tebra are now pushing the technology into a more consequential part of the clinical workflow: prescribing. Their first commercial deployment of FDB Script Agent uses medication intelligence and AI to convert encounter dialogue into structured prescriptions for clinician review, extending automation beyond note-taking while keeping the final decision with the prescriber.
Clinical AI has largely entered the exam room through documentation.
Ambient systems listen to patient-clinician conversations, identify relevant information and generate clinical notes, reducing the amount of time physicians spend documenting encounters. Prescribing, however, has remained comparatively manual.
FDB, or First Databank, and healthcare technology company Tebra are attempting to close that gap with an AI prescribing agent designed to turn conversational intent into structured medication orders.
The companies announced the first commercial deployment of FDB Script Agent through Tebra’s AI Note Assist workflow for independent ambulatory practices. The system interprets the encounter dialogue, applies FDB’s medication intelligence and assembles prescription information for clinician review before anything is sent.
That distinction is important. Script Agent is not intended to autonomously prescribe medication. The clinician can modify, approve or reject each proposed prescription.
Moving ambient AI beyond documentation
Ambient clinical AI has become one of the more visible applications of generative AI in healthcare because documentation is a time-consuming administrative task with a relatively clear human-review process.
Prescription creation introduces a different level of risk.
A system that incorrectly summarizes a conversation can create a poor clinical note. A system that incorrectly interprets medication, dosage or frequency could potentially contribute to patient harm.
FDB is therefore positioning Script Agent around clinical grounding rather than basic natural-language processing.
The platform uses FDB’s medication intelligence to interpret prescribing intent and generate structured prescriptions with clinically relevant elements. According to FDB, it will not stage prescriptions that fall outside normal prescribing practice without an explicit clinician override.
The goal is to create a layer between conversational AI and the electronic health record (EHR), translating what a physician intended to prescribe into a codified order that can be checked before execution.
Why medication intelligence matters
Large language models are increasingly capable of understanding conversational context, but understanding language is not the same as understanding medication.
Prescribing requires structured knowledge about drugs, dosage forms, strengths, routes, dosing schedules and other clinical attributes. It also needs safeguards around unusual or potentially inappropriate instructions.
This is where FDB is attempting to differentiate Script Agent from a generic healthcare chatbot.
The company provides medication information and decision-support technologies used by healthcare organizations, and its platform can supply the structured terminology needed to convert free-form clinical dialogue into prescription data.
For independent medical practices, the potential benefit is straightforward: fewer manual steps between the end of a patient conversation and a prescription that is ready for review.
Tebra makes the technology part of the workflow
The commercial deployment is taking place through Tebra, an all-in-one technology platform serving independent healthcare practices.
Tebra has integrated Script Agent into Tebra AI Note Assist, allowing prescription intelligence to sit alongside ambient clinical documentation rather than forcing clinicians to move between separate applications.
That workflow integration could prove more important than the AI model itself.
Healthcare practices already contend with fragmented software, EHR interfaces and administrative processes. An AI capability that requires another application or separate data-entry workflow can quickly lose its efficiency advantage.
Embedding prescription generation into an existing documentation process creates a more natural path: the system listens to the encounter, generates the clinical note and identifies potential prescriptions from the same conversation.
The clinician remains the checkpoint before the medication order progresses.
The broader race for healthcare workflow automation
FDB and Tebra are entering a rapidly expanding healthcare AI market that includes Microsoft, Google, Amazon, Oracle and numerous specialist clinical-AI vendors.
Much of the competition is moving beyond general-purpose generative AI toward workflow-specific agents that can execute defined tasks within healthcare environments.
Google has invested in healthcare AI and clinical data capabilities, while Microsoft has integrated AI into healthcare workflows through its cloud and clinical technology ecosystem. Electronic health record vendors are also building AI directly into their platforms.
The emerging differentiator is therefore shifting from “who has the best model?” to “who can safely connect AI to a real clinical workflow?”
Prescription automation is a particularly revealing test case because it requires both language understanding and structured medical knowledge.
From prescription generation to the medication journey
FDB’s strategy extends beyond Script Agent.
After a clinician approves a prescription, the company says FDB Vela, its cloud-native electronic prescribing network, can support subsequent steps in the medication process by connecting prescribers, payers, pharmacies and patients.
That creates the outline of a broader prescription-intelligence stack.
Instead of treating AI prescribing as a standalone feature, FDB is positioning it as the front end of a medication workflow that can continue through electronic prescribing and downstream coordination.
For healthcare IT leaders, this architecture is potentially more significant than the initial AI feature. The long-term opportunity lies in connecting conversational AI, clinical decision support, EHR workflows and prescription infrastructure without removing clinicians from the decision loop.
The enterprise adoption question is safety
The biggest barrier to AI prescribing is unlikely to be whether models can interpret a physician’s words. It will be whether healthcare organizations trust the resulting workflow enough to deploy it at scale.
That requires transparent review processes, strong clinical validation, reliable medication terminology and clear accountability.
FDB’s approach—generating a prescription for review rather than automatically transmitting it—is designed around that requirement.
Early feedback from Tebra users, according to the companies, indicates that the workflow is intuitive and reduces prescribing-related administrative effort while maintaining confidence in clinician review.
Those reports are encouraging, but broader adoption will depend on evidence from real-world deployments, error rates and integration with existing EHR and prescribing infrastructure.
The significance of Script Agent ultimately lies in what it represents: healthcare AI is moving from documenting what happened in the exam room toward assisting with what happens next.
If that transition can be made safely, prescription workflows could become one of the next major areas where AI reduces administrative work without eliminating clinical judgment.
Market Landscape
Healthcare AI is shifting from documentation copilots to workflow agents capable of performing structured tasks.
Ambient documentation remains a major entry point because clinicians can review AI-generated notes before they become part of the medical record. Prescription automation raises the stakes because medication orders have direct clinical consequences.
The market is consequently developing around three connected layers: conversational AI, clinical knowledge and workflow infrastructure.
Companies such as Microsoft, Google, Amazon, Oracle and EHR vendors are competing to control different parts of that stack. Specialist providers such as FDB can differentiate through proprietary medication intelligence, terminology and healthcare-specific validation.
For enterprise healthcare teams, the key consideration is not simply model accuracy. Governance, auditability, clinician oversight, EHR integration and the quality of underlying clinical data will determine whether AI prescribing delivers measurable value.
Top Insights
- FDB and Tebra launched the first commercial deployment of Script Agent, bringing AI-powered prescription generation into an existing ambient clinical documentation workflow.
- Script Agent converts encounter dialogue into structured prescriptions using medication intelligence, while clinicians retain authority to modify, approve or reject recommendations.
- The technology addresses a gap in ambient AI, which has automated clinical documentation but historically left prescription entry largely manual.
- FDB’s approach combines large language model capabilities with clinical terminology and medication intelligence, rather than relying on conversational NLP alone.
- Integration with FDB Vela could eventually connect AI-assisted prescription creation with downstream ePrescribing workflows involving payers, pharmacies and patients.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
